重组Anti-FGFR1 (phospho Y653)抗体[EPR843(N)] (ab173305)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR843(N)] to FGFR1 (phospho Y653)
- Suitable for: WB, Dot blot, Indirect ELISA
- Reacts with: Human
Related conjugates and formulations
概述
-
产品名称
Anti-FGFR1 (phospho Y653)抗体[EPR843(N)]
参阅全部 FGFR1 一抗 -
描述
兔单克隆抗体[EPR843(N)] to FGFR1 (phospho Y653) -
宿主
Rabbit -
特异性
This antibody recognizes FGFR1 (phospho Y653), FGFR2 (phospho Y656), FGFR3 (phospho Y647) and FGFR4 (phospho Y642). Furthermore, ab173305 also reacts with FGFR1 (phospho Y654) and FGFR4 (phospho Y643).
-
经测试应用
适用于: WB, Dot blot, Indirect ELISAmore details
不适用于: Flow Cyt,ICC/IF,IHC-P or IP -
种属反应性
与反应: Human -
免疫原
-
阳性对照
- Constitutively active FGFR1.
-
常规说明
This antibody was developed as part of a collaboration between Epitomics and Ira Daar at the National Cancer Institute, NIH.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.20
Constituents: 0.35% Sodium citrate, 0.17% Sodium chloride, 0.03% EDTA, 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
EPR843(N) -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab173305于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
WB |
1/1000. Predicted molecular weight: 92 kDa.
|
|
Dot blot |
1/1000.
|
|
Indirect ELISA |
Use at an assay dependent concentration.
|
说明 |
---|
WB
1/1000. Predicted molecular weight: 92 kDa. |
Dot blot
1/1000. |
Indirect ELISA
Use at an assay dependent concentration. |
靶标
-
功能
Receptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF). -
组织特异性
Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells. -
疾病相关
Defects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity. -
序列相似性
Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
翻译后修饰
Binding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor. -
细胞定位
Membrane. Nucleus. Cytoplasm. Cytoplasmic vesicle - Information by UniProt
-
数据库链接
- Entrez Gene: 2260 Human
- Omim: 136350 Human
- SwissProt: P11362 Human
- Unigene: 264887 Human
-
别名
- Basic fibroblast growth factor receptor 1 antibody
- bFGF-R-1 antibody
- BFGFR antibody
see all
图片
-
All lanes : Anti-FGFR1 (phospho Y653) antibody [EPR843(N)] (ab173305) at 1/1000 dilution
Lane 1 : HEK-293 (human epithelial cell from embryonic kidney transformed with large T antigen) transfected with an empty expression vector, whole cell lysate
Lane 2 : HEK-293 (human epithelial cell from embryonic kidney transformed with large T antigen) transfected with FGFR1 expression vector, whole cell lysate
Lane 3 : HEK-293 (human epithelial cell from embryonic kidney transformed with large T antigen) transfected with FGFR1 expression vector, then the membrane was incubated with alkaline phosphatase for an hour, whole cell lysate
Lane 4 : HEK-293 (human epithelial cell from embryonic kidney transformed with large T antigen) transfected with FGFR1 expression vector and 100 nM Calyculin A for an hour, whole cell lysate
Lane 5 : HEK-293 (human epithelial cell from embryonic kidney transformed with large T antigen) transfected with FGFR1 expression vector and 100 nM Calyculin A for an hour, then the membrane was incubated with alkaline phosphatase for an hour, whole cell lysate
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Developed using the ECL technique.
Predicted band size: 92 kDa
Observed band size: 130 kDa why is the actual band size different from the predicted?
Exposure time: 5 secondsBlocking and diluting buffer: 5% NFDM/TBST.
-
Dot blot analysis of ab173305 at 1/1000 dilution. The secondary antibody used was Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution.
Lane 1: FGFR1 non-phospho peptide
Lane 2: FGFR1 Y653 phospho peptide
Lane 3: FGFR1 Y654 phospho peptide
Lane 4: FGFR1 Y653 + Y654 phospho peptide
Lane 5: FGFR2 non-phospho peptide
Lane 6: FGFR2 Y656 phospho peptide
Lane 7: FGFR2 Y657 phospho peptide
Lane 8: FGFR2 Y656 + Y657 phospho peptide
Lane 9: FGFR3 non-phospho peptide
Lane 10: FGFR3 Y647 phospho peptide
Lane 11: FGFR3 Y648 phospho peptide
Lane 12: FGFR3 Y647 + Y648 phospho peptide
Lane 13: FGFR4 non-phospho peptide
Lane 14: FGFR4 Y642 phospho peptide
Lane 15: FGFR4 Y643 phospho peptide
Lane 16: FGFR4 Y642 + Y643 phospho peptide -
Indirect ELISA analysis of ab173305 at 1/1000 ng/ml. The secondary antibody used was Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution.
Substrate solution: p-nitrophenyl phosphate(PNPP).
-
Indirect ELISA analysis of ab173305 at 1/1000 ng/ml. The secondary antibody used was Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution.
Substrate solution: p-nitrophenyl phosphate(PNPP).
-
Indirect ELISA analysis of ab173305 at 1/1000 ng/ml. The secondary antibody used was Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution.
Substrate solution: p-nitrophenyl phosphate(PNPP).
-
Indirect ELISA analysis of ab173305 at 1/1000 ng/ml. The secondary antibody used was Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution.
Substrate solution: p-nitrophenyl phosphate(PNPP).
数据表及文件
-
SDS download
-
Datasheet download
文献 (9)
ab173305 被引用在 9 文献中.
- Song S et al. EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli. Cell Death Dis 13:351 (2022). PubMed: 35428350
- Li S et al. The Hypoglycemic Effect of JinQi Jiangtang Tablets Is Partially Dependent on the Palmatine-Induced Activation of the Fibroblast Growth Factor Receptor 1 Signaling Pathway. Front Pharmacol 13:895724 (2022). PubMed: 35935824
- Homer-Bouthiette C et al. Gait disturbances and muscle dysfunction in fibroblast growth factor 2 knockout mice. Sci Rep 11:11005 (2021). PubMed: 34040128
- Bhattacharyya S et al. Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer. J Exp Med 217:N/A (2020). PubMed: 32434218
- Li L et al. Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor, suppresses laser-induced CNV in a mouse model of neovascular AMD. J Cell Physiol 235:1259-1273 (2020). PubMed: 31270802
- Zhen C et al. MicroRNA-652 inhibits the biological characteristics of esophageal squamous cell carcinoma by directly targeting fibroblast growth factor receptor 1. Exp Ther Med 18:4473-4480 (2019). PubMed: 31777550
- Liu J et al. Peptide-based NTA(Ni)-nanodiscs for studying membrane enhanced FGFR1 kinase activities. PeerJ 7:e7234 (2019). PubMed: 31372315
- Kang J et al. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Sci Rep 9:8726 (2019). PubMed: 31217507
- Seo HR et al. Intrinsic FGF2 and FGF5 promotes angiogenesis of human aortic endothelial cells in 3D microfluidic angiogenesis system. Sci Rep 6:28832 (2016). WB ; Human . PubMed: 27357248